Brian P. Fiske

Brian P. Fiske

Auto-generated profile, based on publicly available information

Brian P. Fiske

Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA 02139, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2012 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
DADimitrios Anastasiou
Dimitrios Anastasiou
YYYimin Yu
Yimin Yu
WIWilliam J Israelsen
William J Israelsen
JJJian-Kang Jiang
Jian-Kang Jiang
MBMatthew B Boxer
Matthew B Boxer
MHMatthew G Vander Heiden
Matthew G Vander Heiden
A small-molecule activator specific for PKM2 binds to a site distinct from the endogenous activator fructose-1,6-bisphosphate, promoting tetramerization and constitutive activation of PKM2, to inhibit xenograft tumor growth in mice. Cancer cells engage in a metabolic program to enhance biosynthesis and support cell proliferation. The regulatory properties of pyruvate kinase M2 (PKM2) influence altered glucose metabolism in cancer. The interaction of PKM2 with phosphotyrosine-containing proteins inhibits enzyme activity and increases the availability of glycolytic metabolites to support cell proliferation. This suggests that high pyruvate kinase activity may suppress tumor growth. We show that expression of PKM1, the pyruvate kinase isoform with high constitutive activity, or exposure to published small-molecule PKM2 activators inhibits the growth of xenograft tumors. Structural studies reveal that small-molecule activators bind PKM2 at the subunit interaction interface, a site that is distinct from that of the endogenous activator fructose-1,6-bisphosphate (FBP). However, unlike FBP, binding of activators to PKM2 promotes a constitutively active enzyme state that is resistant to inhibition by tyrosine-phosphorylated proteins. These data support the notion that small-molecule activation of PKM2 can interfere with anabolic metabolism.

28 September 2014 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JMJared R Mayers
Jared R Mayers
CWChen Wu
Chen Wu
CCClary Clish
Clary Clish
PKPeter Kraft
Peter Kraft
MTMargaret E Torrence
Margaret E Torrence
BWBrian M Wolpin
Brian M Wolpin
Elevated plasma levels of branched chain amino acids detected prior to pancreatic cancer diagnosis may result from whole body tissue breakdown occurring during the early stages of this disease. Most patients with pancreatic ductal adenocarcinoma (PDAC) are diagnosed with advanced disease and survive less than 12 months1. PDAC has been linked with obesity and glucose intolerance2,3,4, but whether changes in circulating metabolites are associated with early cancer progression is unknown. To better understand metabolic derangements associated with early disease, we profiled metabolites in prediagnostic plasma from individuals with pancreatic cancer (cases) and matched controls from four prospective cohort studies. We find that elevated plasma levels of branched-chain amino acids (BCAAs) are associated with a greater than twofold increased risk of future pancreatic cancer diagnosis. This elevated risk was independent of known predisposing factors, with the strongest association observed among subjects with samples collected 2 to 5 years before diagnosis, when occult disease is probably present. We show that plasma BCAAs are also elevated in mice with early-stage pancreatic cancers driven by mutant Kras expression but not in mice with Kras-driven tumors in other tissues, and that breakdown of tissue protein accounts for the increase in plasma BCAAs that accompanies early-stage disease. Together, these findings suggest that increased whole-body protein breakdown is an early event in development of PDAC.

1 July 2014 in Molecular Cell
Verified
Journal Article
Closed access
CLCaroline A. Lewis
Caroline A. Lewis
SPSeth Parker
Seth Parker
BFBrian P. Fiske
Brian P. Fiske
DMDouglas McCloskey
Douglas McCloskey
DGDan Y. Gui
Dan Y. Gui
CMChristian Metallo
Christian Metallo

1 October 2013 in Cell
Verified
Journal Article
Closed access
WIWilliam J. Israelsen
William J. Israelsen
TDTalya L. Dayton
Talya L. Dayton
SDShawn M. Davidson
Shawn M. Davidson
BFBrian P. Fiske
Brian P. Fiske
AHAaron M. Hosios
Aaron M. Hosios
MHMatthew G. Vander Heiden
Matthew G. Vander Heiden

25 April 2016 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
MPMichael E. Pacold
Michael E. Pacold
KBKyle R Brimacombe
Kyle R Brimacombe
SCSze Ham Chan
Sze Ham Chan
JRJason M Rohde
Jason M Rohde
CLCaroline A Lewis
Caroline A Lewis
DSDavid M Sabatini
David M Sabatini
A quantitative high-throughput screen identified an inhibitor of phosphoglycerate dehydrogenase (PHGDH), a key enzyme for serine synthesis. This inhibitor limits one-carbon unit availability for nucleotide synthesis. Serine is both a proteinogenic amino acid and the source of one-carbon units essential for de novo purine and deoxythymidine synthesis. In the canonical pathway of glucose-derived serine synthesis, Homo sapiens phosphoglycerate dehydrogenase (PHGDH) catalyzes the first, rate-limiting step. Genetic loss of PHGDH is toxic toward PHGDH-overexpressing breast cancer cell lines even in the presence of exogenous serine. Here, we used a quantitative high-throughput screen to identify small-molecule PHGDH inhibitors. These compounds reduce the production of glucose-derived serine in cells and suppress the growth of PHGDH-dependent cancer cells in culture and in orthotopic xenograft tumors. Surprisingly, PHGDH inhibition reduced the incorporation into nucleotides of one-carbon units from glucose-derived and exogenous serine. We conclude that glycolytic serine synthesis coordinates the use of one-carbon units from endogenous and exogenous serine in nucleotide synthesis, and we suggest that one-carbon unit wasting thus may contribute to the efficacy of PHGDH inhibitors in vitro and in vivo.

8 April 2015 in Nature
Verified
Journal Article
Open access
PDF file
DKDohoon Kim
Dohoon Kim
BFBrian P. Fiske
Brian P. Fiske
KBKivanc Birsoy
Kivanc Birsoy
EFElizaveta Freinkman
Elizaveta Freinkman
KKKenjiro Kami
Kenjiro Kami
DSDavid M. Sabatini
David M. Sabatini
Tumours are a low-oxygen environment, in this study glioblastoma cells are found to overexpress the serine hydroxymethyltransferase SHMT2; SHMT acts to reduce oxygen consumption, which confers the tumour cells with a survival advantage. Tumour cells thrive in a low-oxygen environment, and in this study David Sabatini and colleagues demonstrate a mechanism that operates in the ischaemic zone of glioblastoma cells to give tumour cells a survival advantage. Glioblastoma cells are shown to overexpress the serine hydroxymethyltransferase (SHMT2) and glycine decarboxylase (GLDC). SHMT2 favours poorly vascularized tumour cells by reducing oxygen consumption but at the same time it exposes a selective vulnerability. Glycine, the product of SHMT2 activity, if allowed to accumulate in excess within the cell can be converted into toxic molecules, hence it may be possible to target tumorigenic glioblastoma cells by inhibiting GLDC. Cancer cells adapt their metabolic processes to support rapid proliferation, but less is known about how cancer cells alter metabolism to promote cell survival in a poorly vascularized tumour microenvironment1,2,3. Here we identify a key role for serine and glycine metabolism in the survival of brain cancer cells within the ischaemic zones of gliomas. In human glioblastoma multiforme, mitochondrial serine hydroxymethyltransferase (SHMT2) and glycine decarboxylase (GLDC) are highly expressed in the pseudopalisading cells that surround necrotic foci. We find that SHMT2 activity limits that of pyruvate kinase (PKM2) and reduces oxygen consumption, eliciting a metabolic state that confers a profound survival advantage to cells in poorly vascularized tumour regions. GLDC inhibition impairs cells with high SHMT2 levels as the excess glycine not metabolized by GLDC can be converted to the toxic molecules aminoacetone and methylglyoxal. Thus, SHMT2 is required for cancer cells to adapt to the tumour environment, but also renders these cells sensitive to glycine cleavage system inhibition.